Investors & partners
Published cancer biology, a defined lead program, and milestones designed to establish product differentiation.
At a glance
NanomediGene is developing a formulation of a dual ACC1/ACC2 inhibitor for breast cancer. Initial formulation work and an animal pilot are complete. Findings guide follow-up studies of formulation, dose, and schedule.
Request a program briefingThe context
The clinical and commercial landscape informs our development strategy. Product differentiation must be established through NMG’s own studies.
01 / Patient need
New invasive breast-cancer cases among U.S. women in 2026.
This is the broader disease burden. NMG’s eventual eligible patient population remains to be defined.
American Cancer Society · 2026 estimate: 321,91002 / Commercial activity
Reported worldwide sales of an established TROP2-directed medicine.
Commercial context for the field. These sales do not estimate NMG’s market size or future revenue.
Gilead · full-year 2025 results03 / NMG’s direction
An ACC-inhibitor formulation for breast cancer, with improved therapeutic index as the development goal.
Preclinical development. TROP2-directed targeting is planned for evaluation.
Explore our approachInitial formulation work and an animal pilot are complete. Discuss the findings, development priorities, and next studies with our team.
Request a program briefingThe opportunity
Our lead program pairs a metabolic mechanism—ACC1/ACC2 inhibition—with a formulation strategy intended to improve therapeutic index. The development question is whether changing delivery can preserve antitumor activity while improving tolerability relative to the unformulated inhibitor.
We are developing a specific therapeutic formulation. Reproducible manufacturing and comparative studies of activity, exposure, and tolerability will determine its product profile. TROP2-directed targeting is planned and requires validation.
Request an investor discussion
Capital priorities
Formulation optimization, analytical methods, stability, and manufacturing consistency.
Targeting validation and comparative exposure, activity, and tolerability studies.
Candidate selection, development partners, and preparation for IND-enabling work.
Current foundation
Partnering
Our goal is to advance the lead formulation toward clinical readiness and pursue licensing or co-development with oncology partners.
The partnering path will depend on comparative product evidence, manufacturing readiness, financing, and appropriate intellectual-property and development rights.
Contact us for a program briefing covering pilot findings, development requirements, and relevant intellectual-property and licensing information. Detailed study data are available for follow-up discussions.
Alyssa Nicholas
Investor Relations Lead
For investor communications and follow-up: alyssa@nanomedigene.com
Meet AlyssaImportant information
This website is provided for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, any securities. Any securities offering would be made through appropriate offering documents and in accordance with applicable law. Nothing here is investment, legal, or tax advice.
Statements about planned studies, targeting, therapeutic index, manufacturing, financing, partnerships, regulatory development, and future milestones reflect current expectations and involve risks and uncertainties. Actual results and timing may differ materially because of research outcomes, safety or efficacy findings, manufacturing challenges, intellectual-property or licensing matters, financing availability, and regulatory requirements. Preclinical findings do not establish clinical benefit. NMG’s investigational formulations have not been shown to be safe or effective in humans. Statements speak as of their publication date; we undertake no obligation to update them except as required by law.
Read the terms of use